January 17, 2024 — Over the past year, as the world has embraced GLP-1 medicines like semaglutide for obesity, we have heard much speculation about dire prospects for the future of metabolic surgery. Stock prices dropped earlier this year for medical device companies with big investments in bariatric surgery when Intuitive Surgical announced they were seeing a slowdown in […]
January 8, 2024 — Right now, the promise of GLP-1 medicines for obesity, though revolutionary, is serving only to widen the economic rift in health. People with extraordinary wealth or generous health insurance plans receive the health benefits that flow from treating obesity effectively – which include a longer life, fewer strokes, and fewer heart attacks. Others are consigned […]
September 4, 2023 — Health systems seem adept at denial of care for the most prevalent chronic disease in America, obesity. To understand this, just look at the hurdles a patient must clear to receive that most effective treatment with the longest track record: metabolic surgery. The goal is to pick the people for surgery who will have the […]
